Key result
Pyridostigmine treatment resulted in significant improvement in fatigable weakness and treadmill endurance in murine models of myotubular myopathy.
Why the study?
Does pyridostigmine improve fatigable weakness and treadmill endurance in murine models of Myotubular myopathy?
Does pyridostigmine improve fatigable weakness and treadmill endurance in murine models of Myotubular myopathy?
Pyridostigmine, an acetylcholinesterase inhibitor, improves fatigable weakness and treadmill endurance in murine models of Myotubular myopathy, suggesting a potential disease-modifying therapy.
No takes yet. Share an insight, caveat, or question.
Hypothesis-generating for myotubular myopathy therapy; should not change practice without human trials.
Dowling et al. (2012) studied Myotubular myopathy. Pyridostigmine was evaluated on Fatigable weakness and treadmill endurance. Pyridostigmine treatment resulted in significant improvement in fatigable weakness and treadmill endurance in murine models of myotubular myopathy.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: